www.ohiokepro.com
Vol. 2 No. 2
Winter 2004-2005
Influenza Antiviral Medications:
CDC 2004-2005 Interim Chemoprophylaxis
and Treatment Guidelines
CDC 2004-2005 Interim Chemoprophylaxis
and Treatment Guidelines
From the Centers for Disease Control and Prevention
Background
Influenza antiviral medications have long been used to limit the
spread and impact of institutional influenza outbreaks. They also
are used for treatment and chemoprophylaxis of persons in other
settings. In the United States, four antiviral medications (amantadine,
rimantadine, oseltamivir, and zanamivir) are approved for treatment
of influenza, though limited supplies of zanamivir are currently avail-
able. When used for treatment within the first two days of illness,
all four antiviral medications are similarly effective in reducing the
duration of illness by one or two days. Only three antiviral medica-
tions (amantadine, rimantadine, and oseltamivir) are approved for
chemoprophylaxis of influenza. More detailed information about
each medication, including dosage and approved persons for use,
may be found at http://www.cdc.gov/flu/professionals/treatment.
Influenza antiviral medications have long been used to limit the
spread and impact of institutional influenza outbreaks. They also
are used for treatment and chemoprophylaxis of persons in other
settings. In the United States, four antiviral medications (amantadine,
rimantadine, oseltamivir, and zanamivir) are approved for treatment
of influenza, though limited supplies of zanamivir are currently avail-
able. When used for treatment within the first two days of illness,
all four antiviral medications are similarly effective in reducing the
duration of illness by one or two days. Only three antiviral medica-
tions (amantadine, rimantadine, and oseltamivir) are approved for
chemoprophylaxis of influenza. More detailed information about
each medication, including dosage and approved persons for use,
may be found at http://www.cdc.gov/flu/professionals/treatment.
Continued
Influenza Antiviral Medications... (cont.)
I
All persons at high risk of serious influenza complications should
be given antiviral medications if they are likely to be exposed to
others infected with influenza. For example, when a high-risk person
is par t of a family or household in which someone else has been
diagnosed with influenza, the exposed high-risk person should be
given chemoprophylaxis for 7 days.
be given antiviral medications if they are likely to be exposed to
others infected with influenza. For example, when a high-risk person
is par t of a family or household in which someone else has been
diagnosed with influenza, the exposed high-risk person should be
given chemoprophylaxis for 7 days.
(3) Antiviral medications can be considered in other situations
when the available supply of such medications is locally adequate.
when the available supply of such medications is locally adequate.
2004-2005 antiviral medications usage guidelines
CDC is issuing interim recommendations for the use of antiviral
medications during the 2004-2005 season. Local availability of
these medications may var y from community to community, which
could impact how these medications should be used.
The recommendations are as follows:
CDC is issuing interim recommendations for the use of antiviral
medications during the 2004-2005 season. Local availability of
these medications may var y from community to community, which
could impact how these medications should be used.
The recommendations are as follows:
(1) CDC encourages the use of amantadine or rimantadine for
chemoprophylaxis and use of oseltamivir or zanamivir for
treatment as supplies allow, in par t to minimize the development
of amantadine resistance among circulating influenza viruses.
chemoprophylaxis and use of oseltamivir or zanamivir for
treatment as supplies allow, in par t to minimize the development
of amantadine resistance among circulating influenza viruses.
I
I
I
I
I
I
Chemoprophylaxis of persons in communities where influenza
viruses are circulating, which typically lasts for 6-8 weeks.
Persons at high risk of serious complications who are not able
to get vaccinated.
Persons at high risk of serious complications who have been
vaccinated but have not had time to mount an immune response
to the vaccine. In adults, chemoprophylaxis should occur for a
period of 2 weeks after vaccination. In children aged less than 9
years old, chemoprophylaxis should occur for 6 weeks after the
first dose, or 2 weeks after the second dose, depending on whether
the child is scheduled to receive one or two doses of vaccine.
Persons with immunosuppressive conditions who are not expected
to mount an adequate antibody response to influenza vaccine.
Healthcare workers with direct patient care responsibilities who
are not able to obtain vaccine.
Treatment of infected adults and children aged older than 1
year who do not have conditions placing them at high risk for
serious complications secondar y to influenza infection.
viruses are circulating, which typically lasts for 6-8 weeks.
Persons at high risk of serious complications who are not able
to get vaccinated.
Persons at high risk of serious complications who have been
vaccinated but have not had time to mount an immune response
to the vaccine. In adults, chemoprophylaxis should occur for a
period of 2 weeks after vaccination. In children aged less than 9
years old, chemoprophylaxis should occur for 6 weeks after the
first dose, or 2 weeks after the second dose, depending on whether
the child is scheduled to receive one or two doses of vaccine.
Persons with immunosuppressive conditions who are not expected
to mount an adequate antibody response to influenza vaccine.
Healthcare workers with direct patient care responsibilities who
are not able to obtain vaccine.
Treatment of infected adults and children aged older than 1
year who do not have conditions placing them at high risk for
serious complications secondar y to influenza infection.
(2) People who are at high risk of serious complications from
influenza may benefit most from antiviral medications. Therefore, in
general, people who fall into these high-risk groups should be given
priority for use of influenza antiviral medications:
influenza may benefit most from antiviral medications. Therefore, in
general, people who fall into these high-risk groups should be given
priority for use of influenza antiviral medications:
(4) Where the supplies of both influenza vaccine and influenza
antiviral medications may not be sufficient to meet demand, CDC
does not recommend the use of influenza antiviral medications for
chemoprophylaxis of non-high-risk persons in the community.
antiviral medications may not be sufficient to meet demand, CDC
does not recommend the use of influenza antiviral medications for
chemoprophylaxis of non-high-risk persons in the community.
Treatment
Any person experiencing a potentially life-threatening influenza-
related illness should be treated with antiviral medications.
Any person at high risk for serious complications of influenza
and who is within the first 2 days of illness onset should be
treated with antiviral medications. (Pregnant women should
consult their primar y provider regarding use of influenza
antiviral medications.)
Any person experiencing a potentially life-threatening influenza-
related illness should be treated with antiviral medications.
Any person at high risk for serious complications of influenza
and who is within the first 2 days of illness onset should be
treated with antiviral medications. (Pregnant women should
consult their primar y provider regarding use of influenza
antiviral medications.)
I
Rimantadine is not approved for treatment of children under 13
years old. For treatment, these persons should receive amantadine
(children aged 1-12), oseltamivir (children aged 1-12), or
zanamivir (children aged 7-12).
years old. For treatment, these persons should receive amantadine
(children aged 1-12), oseltamivir (children aged 1-12), or
zanamivir (children aged 7-12).
Private sector sources of influenza antiviral medications
Pharmaceutical distributors should be contacted directly for
availability and procurement of antiviral medications.
Pharmaceutical distributors should be contacted directly for
availability and procurement of antiviral medications.
Strategic national stockpile
The United States has a limited supply of influenza antiviral
medications stored in the Strategic National Stockpile (SNS) for
emergency situations. Effor ts are underway by Health and Human
Ser vices to procure additional supplies of antiviral medications. Some
of the supply will be held in reser ve in the event of an influenza
pandemic. However, some of the supply will be made available to
states and territories for use in outbreak settings, as might occur
in a hospital or long-term care facility.
The United States has a limited supply of influenza antiviral
medications stored in the Strategic National Stockpile (SNS) for
emergency situations. Effor ts are underway by Health and Human
Ser vices to procure additional supplies of antiviral medications. Some
of the supply will be held in reser ve in the event of an influenza
pandemic. However, some of the supply will be made available to
states and territories for use in outbreak settings, as might occur
in a hospital or long-term care facility.
Chemoprophylaxis
All persons who live or work in institutions caring for people at
high risk of serious complications of influenza infection should
be given antiviral medications in the event of an institutional
outbreak. This includes nursing homes, hospitals, and other
facilities caring for persons with immunosuppressive conditions,
such as HIV/AIDS. When vaccine is available, vaccinated staff
require chemoprophylaxis only for the 2-week period following
vaccination. Vaccinated and unvaccinated residents should
receive chemoprophylaxis for the duration of institutional out-
break activity. Rapid tests or other influenza tests should be
used to confirm influenza as the cause of outbreaks as soon
as possible. However, treatment and chemoprophylaxis should
be initiated if influenza is strongly suspected and test results
are not yet available. Other outbreak control effor ts such as
cohor ting of infected persons, and the practice of respirator y
hygiene and other measures also should be implemented. For
fur ther information on detection and control of influenza
outbreaks in acute care facilities, please visit
http://www.cdc.gov/ncidod/hip/INFECT/flu_acute.htm.
All persons who live or work in institutions caring for people at
high risk of serious complications of influenza infection should
be given antiviral medications in the event of an institutional
outbreak. This includes nursing homes, hospitals, and other
facilities caring for persons with immunosuppressive conditions,
such as HIV/AIDS. When vaccine is available, vaccinated staff
require chemoprophylaxis only for the 2-week period following
vaccination. Vaccinated and unvaccinated residents should
receive chemoprophylaxis for the duration of institutional out-
break activity. Rapid tests or other influenza tests should be
used to confirm influenza as the cause of outbreaks as soon
as possible. However, treatment and chemoprophylaxis should
be initiated if influenza is strongly suspected and test results
are not yet available. Other outbreak control effor ts such as
cohor ting of infected persons, and the practice of respirator y
hygiene and other measures also should be implemented. For
fur ther information on detection and control of influenza
outbreaks in acute care facilities, please visit
http://www.cdc.gov/ncidod/hip/INFECT/flu_acute.htm.
Requesting influenza antiviral medications from the SNS
Influenza antiviral medications in the SNS can be requested only by
state or territory Health Depar tments. Institutions (hospitals or
long-term care facilities) experiencing an urgent need for such
medications should convey their request to the state or territor y
health depar tment.
1. The state or territor y health depar tment should call
770.488.7100, the CDC's 24/7 emergency number, to make a
request for antiviral medications. A logistics plan is being drafted
and will be available to all state and territorial health departments
in the near future.
2. The state or territor y health depar tment should indicate there
is an urgent priority use situation (as defined previously) that
can be addressed by use of antiviral medications, and should
indicate all reasonable effor ts have been made to procure
influenza antiviral medications from private distributors.
Influenza antiviral medications in the SNS can be requested only by
state or territory Health Depar tments. Institutions (hospitals or
long-term care facilities) experiencing an urgent need for such
medications should convey their request to the state or territor y
health depar tment.
1. The state or territor y health depar tment should call
770.488.7100, the CDC's 24/7 emergency number, to make a
request for antiviral medications. A logistics plan is being drafted
and will be available to all state and territorial health departments
in the near future.
2. The state or territor y health depar tment should indicate there
is an urgent priority use situation (as defined previously) that
can be addressed by use of antiviral medications, and should
indicate all reasonable effor ts have been made to procure
influenza antiviral medications from private distributors.
For more information, visit www.cdc.gov/flu or call the National
Immunization Hotline at 800-232-2522 (English), 800-232-0233
(Español), or 800-243-7889 (TTY).
Immunization Hotline at 800-232-2522 (English), 800-232-0233
(Español), or 800-243-7889 (TTY).
Providers Urged to Promote Pneumococcal Vaccine
0-11/2003. This materi
Publication No. 4020-OH-01
Publication No. 4020-OH-01
Pneumococcal pneumonia kills more people ever y year than all
other vaccine-preventable diseases combined, according to the
Centers for Disease Control and Prevention (CDC). The CDC estimates
that as many as 40,000 Americans die from pneumonia each year.
other vaccine-preventable diseases combined, according to the
Centers for Disease Control and Prevention (CDC). The CDC estimates
that as many as 40,000 Americans die from pneumonia each year.
The federal government's goal is to have 90 percent of the elderly
vaccinated against pneumococcal disease by 2010; about 63
percent of the elderly are cur rently vaccinated. Medicare claims data
for 2002 suggest that in Ohio about 640,000 of 1.1 million
Medicare beneficiaries over age 65 need a pneumonia shot.
vaccinated against pneumococcal disease by 2010; about 63
percent of the elderly are cur rently vaccinated. Medicare claims data
for 2002 suggest that in Ohio about 640,000 of 1.1 million
Medicare beneficiaries over age 65 need a pneumonia shot.
High-risk individuals requiring the pneumococcal vaccination include:
People who are age 65 or older.
I People who have chronic illnesses.
I People with hear t or lung diseases.
I People with diabetes mellitus.
I People with sickle cell disease, alcoholism, chronic liver diseases,
or cerebrospinal fluid leaks.
I People with a weak immune system.
I People with human immunodeficiency vir us (HIV), or AIDS.
I People with chronic renal failure, or or gan transplantation.
I People with Hodgkin's disease, lymphoma, multiple myeloma, and
those who have had their spleen removed.
I Residents of nursing homes or other long-ter m care facilities.
People who are age 65 or older.
I People who have chronic illnesses.
I People with hear t or lung diseases.
I People with diabetes mellitus.
I People with sickle cell disease, alcoholism, chronic liver diseases,
or cerebrospinal fluid leaks.
I People with a weak immune system.
I People with human immunodeficiency vir us (HIV), or AIDS.
I People with chronic renal failure, or or gan transplantation.
I People with Hodgkin's disease, lymphoma, multiple myeloma, and
those who have had their spleen removed.
I Residents of nursing homes or other long-ter m care facilities.
I
Flu shots
Given the cur rent flu vaccine shor tage, Ohio KePRO also reminds
healthcare providers to of fer flu shots only to those deemed high-
risk by the Advisor y Committee on Immunization Practices (ACIP).
Given the cur rent flu vaccine shor tage, Ohio KePRO also reminds
healthcare providers to of fer flu shots only to those deemed high-
risk by the Advisor y Committee on Immunization Practices (ACIP).
The following priority groups for vaccination with inactivated influenza
vaccine this season are considered to be of equal impor tance and
include:
I All children aged 623 months.
I Adults aged 65 years and older.
I Persons aged 264 years with underlying chronic medical conditions.
I All women who will be pregnant during the influenza season.
I Residents of nursing homes and long-ter m care facilities.
I Children aged 6 months-18 years on chronic aspirin therapy.
vaccine this season are considered to be of equal impor tance and
include:
I All children aged 623 months.
I Adults aged 65 years and older.
I Persons aged 264 years with underlying chronic medical conditions.
I All women who will be pregnant during the influenza season.
I Residents of nursing homes and long-ter m care facilities.
I Children aged 6 months-18 years on chronic aspirin therapy.
I
Healthcare workers involved in direct patient care.
Out-of-home caregivers and household contacts of children aged
less than 6 months.
Out-of-home caregivers and household contacts of children aged
less than 6 months.
I
Other flu vaccination recommendations include the following:
I Persons in priority groups identified above should be encouraged
to search locally for vaccine if their regular healthcare provider
does not have vaccine available.
I Intranasally administered, live, attenuated influenza vaccine, if
available, should be encouraged for healthcare workers (except
those who care for severely immunocompromised patients in
special care units) and persons caring for children aged less than
6 months.
I Cer tain children aged less than 9 years require two doses of
vaccine if they have not previously been vaccinated. All children at
high risk for complications from influenza, including those aged
6-23 months, who are brought for vaccination should be vaccinated
with a first or second dose, depending on vaccination status.
However, doses should not be held in reser ve to ensure that two
doses will be available. Instead, available vaccine should be used
to vaccinate persons in priority groups on a first-come, first-ser ved
basis.
I Persons in priority groups identified above should be encouraged
to search locally for vaccine if their regular healthcare provider
does not have vaccine available.
I Intranasally administered, live, attenuated influenza vaccine, if
available, should be encouraged for healthcare workers (except
those who care for severely immunocompromised patients in
special care units) and persons caring for children aged less than
6 months.
I Cer tain children aged less than 9 years require two doses of
vaccine if they have not previously been vaccinated. All children at
high risk for complications from influenza, including those aged
6-23 months, who are brought for vaccination should be vaccinated
with a first or second dose, depending on vaccination status.
However, doses should not be held in reser ve to ensure that two
doses will be available. Instead, available vaccine should be used
to vaccinate persons in priority groups on a first-come, first-ser ved
basis.
Vaccinations of persons in nonpriority groups
Persons who are not included in one of the priority groups described
above should be infor med about the ur gent flu vaccine supply
situation and asked to forego or defer vaccination.
Persons who are not included in one of the priority groups described
above should be infor med about the ur gent flu vaccine supply
situation and asked to forego or defer vaccination.
People who should not receive a flu shot
There are some people who should not be vaccinated. These include:
I People who have a severe aller gy to chicken eggs.
I People who have had a severe reaction to an influenza vaccination
in the past.
I People who developed Guillain-Bar ré syndrome (GBS) within 6
weeks of getting an influenza vaccine previously.
I Children less than 6 months of age.
I People who are sick with a fever. (These people can get vaccinated
once their symptoms lessen.)
There are some people who should not be vaccinated. These include:
I People who have a severe aller gy to chicken eggs.
I People who have had a severe reaction to an influenza vaccination
in the past.
I People who developed Guillain-Bar ré syndrome (GBS) within 6
weeks of getting an influenza vaccine previously.
I Children less than 6 months of age.
I People who are sick with a fever. (These people can get vaccinated
once their symptoms lessen.)
Practical steps to help prevent spread of flu
Although vaccination is the best protection against influenza, Ohio
KePRO and the CDC remind healthcare providers to ur ge their
patients to take the following practical steps to help prevent the
spread of flu:
I Avoid close contact with people who are sick and keep your
distance from others if you're sick.
I When possible, stay home from work and
school and avoid r unning er rands when
you're sick.
I Cover your mouth and nose when coughing
or sneezing.
I Wash your hands often.
Although vaccination is the best protection against influenza, Ohio
KePRO and the CDC remind healthcare providers to ur ge their
patients to take the following practical steps to help prevent the
spread of flu:
I Avoid close contact with people who are sick and keep your
distance from others if you're sick.
I When possible, stay home from work and
school and avoid r unning er rands when
you're sick.
I Cover your mouth and nose when coughing
or sneezing.
I Wash your hands often.
For more infor mation, please contact Ohio
KePRO's Physician Of fice Team at
1-800-385-5080; e-mail:
droffice@ohqio.sdps.org. Ohio KePRO
also of fers free flu and pneumonia
materials such as the pneumonia poster
(above) and pneumonia brochure (right)
for healthcare providers. To order,
please call 1-800-385-5080, or visit
www.ohiokepro.com and click on
"Shopping Bag." I
KePRO's Physician Of fice Team at
1-800-385-5080; e-mail:
droffice@ohqio.sdps.org. Ohio KePRO
also of fers free flu and pneumonia
materials such as the pneumonia poster
(above) and pneumonia brochure (right)
for healthcare providers. To order,
please call 1-800-385-5080, or visit
www.ohiokepro.com and click on
"Shopping Bag." I
ur Life
CDC, Aventis Pasteur Announce Allocation Plan to
Address Influenza Vaccine Shor tages
Address Influenza Vaccine Shor tages
From the Centers for Disease Control and Prevention
A
s this issue of Quality Connection was going
to press, the Centers for Disease Control and
Prevention (CDC) and Aventis Pasteur announced
the first phase of the plan to allocate influenza
vaccine in response to the recently announced loss
of one-half of the nation's expected flu vaccine
supply for the 2004-2005 season. The plan,
announced by CDC Director Dr. Julie Gerberding and
Aventis Pasteur US President Damian Braga, calls
for CDC to work closely with Aventis to distribute
22.4 million doses of unshipped vaccine in phases
to identified areas of need throughout the countr y.
to press, the Centers for Disease Control and
Prevention (CDC) and Aventis Pasteur announced
the first phase of the plan to allocate influenza
vaccine in response to the recently announced loss
of one-half of the nation's expected flu vaccine
supply for the 2004-2005 season. The plan,
announced by CDC Director Dr. Julie Gerberding and
Aventis Pasteur US President Damian Braga, calls
for CDC to work closely with Aventis to distribute
22.4 million doses of unshipped vaccine in phases
to identified areas of need throughout the countr y.
Beginning immediately, about 14.2 million doses
of vaccine will be allocated over a period of six to
eight weeks through Aventis Pasteur contracts
directly to high-priority vaccine providers, including
hospitals, long-ter m care facilities, nursing homes,
and private providers who care for young children.
of vaccine will be allocated over a period of six to
eight weeks through Aventis Pasteur contracts
directly to high-priority vaccine providers, including
hospitals, long-ter m care facilities, nursing homes,
and private providers who care for young children.
"This plan will help ensure that vaccine gets to
those people who need it most," said CDC Director
Dr. Julie Gerberding. "This is a troubling, fr ustrating
situation for all of us and we need for all Americans
to pull together in the weeks to come to meet this
challenge head-on. This plan is the result of
unprecedented collaboration between CDC, Aventis
Pasteur, and state and local health depar tments
across the countr y. And we must not for get the
other public health heroes on the front lines in
grocer y stores, phar macies, and health clinics
working to prioritize vaccine."
those people who need it most," said CDC Director
Dr. Julie Gerberding. "This is a troubling, fr ustrating
situation for all of us and we need for all Americans
to pull together in the weeks to come to meet this
challenge head-on. This plan is the result of
unprecedented collaboration between CDC, Aventis
Pasteur, and state and local health depar tments
across the countr y. And we must not for get the
other public health heroes on the front lines in
grocer y stores, phar macies, and health clinics
working to prioritize vaccine."
"Since Dr. Gerberding contacted us, we at Aventis Pasteur have worked with the
CDC around the clock to tackle the complex task of getting millions of doses of
influenza vaccine to thousands of healthcare providers around the countr y," said
Damian Braga, president, Aventis Pasteur US. "Our goal has been to direct remaining
doses as quickly as possible to those areas where large numbers of at-risk individuals
are in need. It is a huge logistical feat and we are proud to have contributed our
knowledge and exper tise to this plan." I
CDC around the clock to tackle the complex task of getting millions of doses of
influenza vaccine to thousands of healthcare providers around the countr y," said
Damian Braga, president, Aventis Pasteur US. "Our goal has been to direct remaining
doses as quickly as possible to those areas where large numbers of at-risk individuals
are in need. It is a huge logistical feat and we are proud to have contributed our
knowledge and exper tise to this plan." I
CALENDAR OF EVENTS
Save the Date!
will open on Monday, October 25, 2004.
Par ticipants should register at
http://registration.intercall.com/go/cms.
Registration after 12 p.m., November 15,
2004 will delay confirmation and individuals
may not be permitted entrance to the building.
Persons par ticipating by teleconference
should dial: 1-877-357-7851 and
Reference Conference ID: 1040512.
Par ticipants should register at
http://registration.intercall.com/go/cms.
Registration after 12 p.m., November 15,
2004 will delay confirmation and individuals
may not be permitted entrance to the building.
Persons par ticipating by teleconference
should dial: 1-877-357-7851 and
Reference Conference ID: 1040512.
November 16, 2004
Centers for Medicare & Medicare Ser vices
(CMS) Town Hall Meeting
2:00 p.m. to 3:00 p.m. (ET)
The purpose of the meeting is to provide
the Agency with a venue that would allow
access to individual Medicare providers for
CMS managers, who need provider opinion
on various topics. At the meeting, CMS Staff
will explain the CMS design for getting indi-
vidual provider feedback on CMS provider
communications and other topics.
Centers for Medicare & Medicare Ser vices
(CMS) Town Hall Meeting
2:00 p.m. to 3:00 p.m. (ET)
The purpose of the meeting is to provide
the Agency with a venue that would allow
access to individual Medicare providers for
CMS managers, who need provider opinion
on various topics. At the meeting, CMS Staff
will explain the CMS design for getting indi-
vidual provider feedback on CMS provider
communications and other topics.
Encore is a digital recording of this call, which
will be available hours after the meeting and
can be accessed by dialing 1-800-642-1687
and entering the Conf. ID number 1040512.
will be available hours after the meeting and
can be accessed by dialing 1-800-642-1687
and entering the Conf. ID number 1040512.
Online registration is available for individuals
to par ticipate in the meeting, whether in
person or by teleconference. Par ticipation
Instructions: Registration for the meeting
to par ticipate in the meeting, whether in
person or by teleconference. Par ticipation
Instructions: Registration for the meeting
Please contact Keri Boston at
Kboston@cms.hhs.gov for fur ther information
about registration for the meeting.
Kboston@cms.hhs.gov for fur ther information
about registration for the meeting.
Publication No. 4031-OH-002-11/2004. This material was prepared by Ohio KePRO, the Medicare
Quality Improvement Organization for Ohio, under contract with the Centers for Medicare &
Medicaid Ser vices (CMS), an agency of the U.S. Depar tment of Health and Human Ser vices.
The contents presented do not necessarily reflect CMS policy.
Quality Improvement Organization for Ohio, under contract with the Centers for Medicare &
Medicaid Ser vices (CMS), an agency of the U.S. Depar tment of Health and Human Ser vices.
The contents presented do not necessarily reflect CMS policy.
Ohio KePRO Physician Office Team
CDC will continue to work with Aventis Pasteur and
state and local health depar tments to identify
people, by region, on the vaccination priority list.
The approximately 8.2 million doses remaining
after the first phase is completed will be shipped
to other high-need areas.
state and local health depar tments to identify
people, by region, on the vaccination priority list.
The approximately 8.2 million doses remaining
after the first phase is completed will be shipped
to other high-need areas.
Alice Stollenwerk Petrulis, MD, FACP
Betty Pilous, RN, MHSA, CPHQ
Bonnie Hollopeter, LPN, CPHQ
Sandy Gallagher, MPA
Steve Cramer, BS
Betty Pilous, RN, MHSA, CPHQ
Bonnie Hollopeter, LPN, CPHQ
Sandy Gallagher, MPA
Steve Cramer, BS
Leslie Crowe, LPN, BS
Kerri Gilligan, RN, CPHQ
Marsha Hopper, RN
Kathleen Korosi, MPA
Svetlana Marchuk, BS
Kerri Gilligan, RN, CPHQ
Marsha Hopper, RN
Kathleen Korosi, MPA
Svetlana Marchuk, BS
Executive Editor : Suzana C. Iveljic, MBA
Editor : Robert A. Feigenbaum, MS
Marilyn Monteiro
Patricia Moynihan, AAB
Julie Ondercin, RHIA, CPHQ
Linda Wozniak, LPN
Dan Ziemnik, BA
Patricia Moynihan, AAB
Julie Ondercin, RHIA, CPHQ
Linda Wozniak, LPN
Dan Ziemnik, BA
Ohio KePRO Provider QIC Line--Your Quality Improvement Connection: 1-800-385-5080
Medicare Help Line: 1-800-MEDICARE (1-800-633-4227) e-mail: droffice@ohqio.sdps.org
Medicare Help Line: 1-800-MEDICARE (1-800-633-4227) e-mail: droffice@ohqio.sdps.org
I
I
I